Monitoring Tumor-informed Circulating Tumor DNA after CGP
en-GBde-DEes-ESfr-FR

Monitoring Tumor-informed Circulating Tumor DNA after CGP

15/01/2025 Tohoku University

Researchers from Iwate Medical University and Tohoku University have revealed that it is possible to predict cancer relapse and treatment response by measuring circulating tumor DNA (ctDNA), in tandem with data from comprehensive genomic profiling (CGP).

CGP test results can be used to tailor recommendations for advanced cancer treatment, with the goal of matching individual patients with the most effective option to prolong survival. This study retrospectively looked at the CGP and clinical data of 219 patients of Iwate Medical University with advanced cancer registered with the Center for Personalized Medicine at Tohoku University Hospital. Of these patients, only 14 (6.4%) received a tailored treatment based on their CGP results.

The research team proposed that patients who underwent CGP could undergo ctDNA monitoring by using digital PCR (dPCR) (Off The Shelf-assay, hereafter OTS-Assay). The OTS-Assay was originally developed at Iwate Medical University, and has been clinically validated for a number of different cancers. Strengthening our knowledge and further testing the validity of this system is crucial, so that it can potentially become more commonplace in clinical practice.

"First, we complete CGP to recommend an ideal treatment. Then, we can further predict and monitor the efficacy of that treatment using a relevant ctDNA - a measure of tumor DNA in the blood that can pick up even minimal hints that the cancer is still persisting," explains Satoshi Nishizuka (Iwate Medical University).

The clinical validity of the OTS-Assay was evaluated for "early relapse prediction," "treatment response evaluation," and "no relapse/regrowth corroboration". Monitoring of ctDNA by dPCR was performed in 11 patients. Overall, 10 of 11 patients (90.9%) achieved at least one of the following validated outcomes: "early relapse prediction," "treatment response evaluation," and "no relapse/regrowth corroboration".

This study demonstrated that ctDNA monitoring using the OTS-Assay system can be used effectively in conjunction with CGP data in order to predict patient outcomes for a broad range of cancer types. This finding represents a step forward for personalized precision medicine. Importantly, the majority of patients who receive CGP but do not actually receive a recommended treatment (the remaining 93.6%) can still undertake ctDNA monitoring using the OTS-Assay system to evaluate their disease progression. This type of personalized medical care could improve clinical management techniques, and ultimately help cancer patients around the world.

https://www.tohoku.ac.jp/en/press/monitoring_circulating_tumor_dna_after_cgp.html
Title: Comprehensive genome profiling-initiated tumor-informed circulating tumor DNA monitoring for patients with advanced cancer
Authors: Taiga Sasaki, Hayato Hiraki, Akiko Yashima-Abo, Hiromi Nagashima, Fumitaka Endo, Mizunori Yaegashi, Shimpei Miura, Keiko Obata, Naoki Yanagawa, Hiroaki Itamochi, Hidekazu Shirota, Takeshi Iwaya, Satoshi S. Nishizuka
Journal: Cancer Science
DOI: 10.1111/cas.16446
Attached files
  • (A) Breakdown CGP by organ(s) of origin. (B) The percentage of patients with mutations that could not be matched with a relevant drug; The percentage of patients that obtained a subsequent treatment recommendation based on CGP; the percentage of patients who actually received the recommended next treatment; the percentage of patients who also received ctDNA monitoring in the present cohort. ©Sasaki et al.
  • OTS-Scan analyzes the results of OTS-Scan using a proprietary algorithm to list gene mutations more closely related to cancer. OTS-Monitor quantifies the gene mutations selected by OTS-Select every few months. ©Sasaki et al.
  • The columns on the right show that clinical validity was confirmed in 10 out of 11 cases. Cases classified as having a progressive on imaging showed that corresponding variant allele frequencies (VAFs) also increased. For five cases in which early relapse was considered likely to occur, the average lead time was 43 days of the disease progression confirmed by imaging. In two cases that showed VAFs remained below detection limit (BDL, <0.01%), clinical findings of no relapse/regrowth were well supported. One case of pancreatic cancer, the VAFs remained below detection limit, despite disease progression on imaging, possibly due to the DNA of the pancreas being highly fragmented. ©Sasaki et al.
15/01/2025 Tohoku University
Regions: Asia, Japan
Keywords: Science, Chemistry, Life Sciences, Health, Medical

Disclaimer: AlphaGalileo is not responsible for the accuracy of news releases posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.

Testimonials

For well over a decade, in my capacity as a researcher, broadcaster, and producer, I have relied heavily on Alphagalileo.
All of my work trips have been planned around stories that I've found on this site.
The under embargo section allows us to plan ahead and the news releases enable us to find key experts.
Going through the tailored daily updates is the best way to start the day. It's such a critical service for me and many of my colleagues.
Koula Bouloukos, Senior manager, Editorial & Production Underknown
We have used AlphaGalileo since its foundation but frankly we need it more than ever now to ensure our research news is heard across Europe, Asia and North America. As one of the UK’s leading research universities we want to continue to work with other outstanding researchers in Europe. AlphaGalileo helps us to continue to bring our research story to them and the rest of the world.
Peter Dunn, Director of Press and Media Relations at the University of Warwick
AlphaGalileo has helped us more than double our reach at SciDev.Net. The service has enabled our journalists around the world to reach the mainstream media with articles about the impact of science on people in low- and middle-income countries, leading to big increases in the number of SciDev.Net articles that have been republished.
Ben Deighton, SciDevNet

We Work Closely With...

  • BBC
  • The Times
  • National Geographic
  • The University of Edinburgh
  • University of Cambridge
  • iesResearch
Copyright 2025 by AlphaGalileo Terms Of Use Privacy Statement